Published in
BioMed Central, Arthritis Research and Therapy, 3(14), p. R143
DOI: 10.1186/ar3876
Links
- ORCID
- ORCID
- BioMed Central | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [arthritis-research.com] | PDF
- [espace.library.uq.edu.au]
- [ecite.utas.edu.au] | PDF
- [digital.library.adelaide.edu.au] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study
,
Karen Patterson,
Pravin Hissaria,
Janet Roddy,
Jane Zochling,
Joanne Sahhar,
Peter Nash ,
Kathleen Tymms,
David Celermajer,
Eli Gabbay
and other authors.
Full text: Download
Abstract
Abstract Introduction Pulmonary arterial hypertension is a major cause of mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide (NT-proBNP) has emerged as a candidate biomarker that may enable the early detection of systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). The objective of our study was to incorporate NT-proBNP into a screening algorithm for SSc-PAH that could potentially replace transthoracic echocardiography (TTE) as a more convenient and less costly "first tier" test. Methods NT-proBNP levels were measured in patients from four clinical groups: a group with right heart catheter (RHC)-diagnosed SSc-PAH before commencement of therapy for PAH; a group at high risk of SSc-PAH based on TTE; a group with interstitial lung disease; and systemic sclerosis (SSc) controls with no cardiopulmonary complications. NT-proBNP levels were compared by using ANOVA and correlated with other clinical variables by using simple and multiple linear regression. ROC curve analyses were performed to determine the optimal cut point for NT-proBNP and other clinical variables in prediction of PAH. Results NT-proBNP was highest in the PAH group compared with other groups ( P